higher Cr tissue levels in males and females above control levels. Male mice showed fiveto sixfold Cr accumulation above controls in the spleen and liver. Female mice showed 5-fold higher Cr levels in lung, and fourfold increases in the spleen, above controls. Other organs were two-to fourfold higher in Ci' than controls for both sexes. An identical study in rats resulted in threefold higher Cr levels in the spleen and heart of young males and twofold highem' levels in the lung and spleen of old females; however, other organ Cr levels were equivalent to or less than those in controls for other treatment groups (16 i"p''-tion and handling among regions ('all m'at'ely be controlled (23) . Recent studies with improved aimalyt ical methitds have failed to confirm an age differemire for Ci' tissue levels in subjects from Finland (24) and Canada (25), whereas Cr levels in subjects from the U.K. were actually found to increase with age and renal disease (26) . Accumulation of Cr(III) in humans has mainly l)een observed in studies of occupational exposure to Ci'. Chm'omimim accumulation has been correlated svith increased incidences of lung cancer iti worket's occupationally expose(l to Cm'. Chii'omium was measured in the lungs of ('hromate work- em's who died of lung cancer at levels of 40 to 468 g Ct'/g dry tissue (27) . This corresponds to a wet tissue Cr concentration of 0.2 to 2 mM. Most importatit. the autopsies were pet'formned on workers 15 to 20 years after their last Cr exposure. Accumulation does not occur solely imi the respim'atoty organs of workers exposed to Cm' by inhalation.
High tisstme levels of Cr were also measured in the spleen, liver, kidney, and heam't of Japanese metallic workers (28). Occupational exposum'e is also not limited to Cm'(VI). Tatinery workers exposed to Cr(III) weie found to have mean serum levels of 9 nM Cm'(range 7 to 16 nM) compared to mean levels of 3 nM Cr (range 2 to 4 nM) in contm'ol subjects (29) 
1)
workers can be exposed to 1)0th Cm'(VI) amid Cr(II1) in a given occupational setting; 2) aftet' Cr(VI) enters a cell, it is reduced to amid accumulates as Cr(lIl), and 3) although studies of Cr(III) with whole cells are limited by poot' uptake of Cr(III) (36) 
B.
ment 3 will still be present 3 years after the ingestiomi. As expected, the simple model follows this estimate. A simigle dose of 3 capsules of CrPic (5.01 mg) with 2.8% absom'pLion (9) delivers 14 J.tg of CrPic to compartnbemit 3. One year after this single dose, 11 .tg are retaimied (Fig. lit) of Cr supplemetits will lead to significant buildup of Cr in the medium and slow functional compartments. A lower limit for the retained level after daily ingestion of 5.01 mg of Ci'Pic with 2.8% absorption may be computed for 1 year of ingestion by multiplyimig the 1 year retained level from a single dose by 365, predicting 4015 jig of CrPic. Tile calculated value will be greater than this estimnate, because a full year is required for a single close to fall to 11 jIg and only the first dose will experience this time spami. Application of the model over a 1 year period to obtain a more accurate calculation predicts that the Ct'Pic level in compartmiient 2 reaches a steady state after 3 mnonths, whereas the level in compat'tment 1 rises with ingestion but falls back to < 5 jIg at the end of the day, amid the level in compartmnent 3 steadily increases.
At the end of 1 year of dosimig, nearly 6200 jig of Ci'Pic will be m'etaimiecl (Fig. 1B) We may also obtain information omi the time necessary to remove this Cr from the body. Assuming that ingestion ceases after a single year of daily dosing (Fig. IB) , 1 year aftet' the last dose 3600 Jig of the origimial 6200 jIg of CrPic still m'emain (Fig. 1C) . Twenty years are requim'ed for this level to be reduced to 46 Mg.
Predictions from the Lim model
To ascertain whether these results are simply an am'tifact of the sinbple model, we completed an idemitical study usimig the atbalysis of Lim et al. (39) . Although the fumictional model is more complex, with 10 rather than 3 rate constants involved, the results were similar. (Fig. 2B) as opposed to 6200 Mg in the Gam'gas model (Fig. 1B) 
RELEVANCE OF MODELS TO CHROMIUM SUPPLEMENT STUDIES IN HUMANS
Bunker and co-workem's (4) studied the 5 day dietary uptake ambd exct'etion of Cr imi 22 healthy elderly subjects consuming self-selected diets averaging 24.5 Jig Ci'/day.
The mean ut'inamy excretion (minimum absorption) of Cr was 1.7% of the dietamy intake and the mean fecal excretion was 97.7%.
The 0.6% of dietary Cr utiaccounted for was labeled tiet retentiomi hut was not distinguishable from nonurinary/fecal excretion.
A second study on 12
day Cr balances imi two normal males consummimig 36.8 jig
Cr/day (6) yielded consistent results. Urinamy excretion of Cr for both subjects was 0.8% of dietary intake and average fecal excretion was 98.1%. Net retention/secondary excretion averaged 1.0%. The pharmacokimietic calculations of Gargas (9) and Lim (39) were applied to the data obtaimied in the study with 22 subjects (4). These models estimate long-term Cr balances better than short-term balances largely because the second storage pool requit'es several half-lives to establish a steady state (Fig. 1, Fig. 2) . Calculations for shorter time points result in overestimates.
Although the clinical study measured 5 dlay periods for each subject, the fact that the diets were self selected allows the assumption that these values model bug-term To stmmmarize. the pharmacokinetic models project that over the coum'se of several wk to 1 year of contimiual dosing, a substantial level of the absorbed Cr(III) will be retained; however, these model predictions am'e two-to fout'fold niore conset'-vative than the three actual clinical results (4, 6, 8) . 
IMPLICATIONS FOR CHROMIUM DIETARY SUPPLEMENTS

